BioCina and NovaCina form strategic alliance

Microbial development and contract manufacturing companies Adelaide’s BioCina and Perth’s NovaCina have announced a strategic partnership to provide integrated drug substance and drug product solutions for the pharmaceutical sector. The two companies are buy-outs from the Pfizer pharmaceutical company and share the same investor – private investment firm Bridgewest Group – and will now collaborate…

BridgeWest adds NovaCina to pharmaceutical assets

Private investment firm, Bridgewest Group has expanded its pharmaceuticals portfolio, announcing the purchase of the sterile injectable manufacturing facility of Pfizer (Perth) Pty Ltd, a subsidiary of Pfizer, Inc. The cGMP manufacturing facility, located in Bentley, Perth is a diverse sterile injectable manufacturing facility, approved to supply drug products in over 90 countries with approvals…

Viatris medicines gain Australian Made logo

Healthcare manufacturer Viatris Australia has announced the Australian Made, Australian Grown (AMAG) logo has now been added to 50 of its Australian medicine products. In what the company describes as a first for a prescription medicine manufacturer in Australia, 50 products manufactured in Carole Park, Queensland, now showcase the logo. Products bearing the AMAG logo…

Manufacturing news briefs – stories you might have missed

IDT Australia raises $2 million from shareholders Melbourne pharmaceutical manufacturer IDT Australia has raised $2 million via an over-subscribed share purchase plan to existing shareholders. The raising followed the successful completion of a $5 million placement to professional and sophisticated investors. The total capital raised will be used to fund the company’s capital expenditure programme…

IDT’s strong quarter delivers growth

Pharmaceutical manufacturer IDT Australia is seeing a surge in sales as demand for medical cannabis products rises and companies seek out more capable contract development and manufacturing organisations (CDMO). The Melbourne company told investors that revenues increased for the fourth quarter, with 4QFY23 revenue up 200 percent on the previous corresponding period to $2.4 million.…